Ramanath Dukkipati, MD
Nephrology · Northridge, CANPI 1457570376
Payments from drug & device makers
Across 393 payments — averaging $179.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$37K
- Bayer$27K
- Amgen$1K
- Otsuka America Pharmaceutical, Inc.$874
- Akebia Therapeutics Inc$493
- Novartis$489
- plus $3K from 20 others
What the payments were for
- Speaking & faculty fees$61,18387%
- Travel & lodging$9531%
- Food & beverage$8,02811%
- Education$2080%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 90 | $37,384 |
| Bayer | 31 | $26,968 |
| Amgen(2 entities) | 99 | $1,376 |
| Otsuka America Pharmaceutical, Inc. | 28 | $874 |
| Akebia Therapeutics Inc | 23 | $493 |
| Novartis | 22 | $489 |
| Vifor Pharma, Inc. | 14 | $473 |
| GSK | 19 | $456 |
| Travere Therapeutics, Inc. | 12 | $236 |
| Mallinckrodt Hospital Products Inc. | 6 | $229 |
| Calliditas Therapeutics US Inc. | 10 | $212 |
| EMD Serono, Inc. | 6 | $198 |
| Novo Nordisk | 7 | $192 |
| Medtronic | 1 | $142 |
| Ardelyx, Inc. | 5 | $109 |
| Lilly USA, LLC | 4 | $98 |
| Boehringer Ingelheim | 3 | $88 |
| Nxstage Medical, Inc. | 1 | $77 |
| Sanofi | 3 | $70 |
| Aurinia Pharma U.S., Inc. | 2 | $51 |
| Ultragenyx Pharmaceutical Inc. | 2 | $44 |
| Alnylam Pharmaceuticals Inc. | 1 | $32 |
| ANI Pharmaceuticals, Inc. | 1 | $27 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Fresenius USA Marketing, Inc. | 1 | $20 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$70,372 in reported general payments places this provider in the 85th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XphozahTenapanor Hcl | 27 | $80,721 |
| FarxigaDapagliflozin Propanediol | 102 | $77,107 |
| Tolvaptan | 33 | $67,363 |
| ProcritEpoetin Alfa | 40 | $56,525 |
| VeltassaPatiromer Calcium Sorbitex | 54 | $41,826 |
| VelphoroSucroferric Oxyhydroxide | 14 | $40,012 |
| LokelmaSodium Zirconium Cyclosilicate | 69 | $34,877 |
| KerendiaFinerenone | 20 | $29,213 |
| AuryxiaFerric Citrate | 17 | $17,782 |
| RetacritEpoetin Alfa-Epbx | 11 | $13,485 |
| ProsolParenteral Amino Acid 20% No.1 | 53 | $9,216 |
| Sevelamer Carbonate | 37 | $7,926 |
| Cinacalcet Hcl | 28 | $7,658 |
| DapagliflozinDapagliflozin Propanediol | 13 | $7,027 |
| JardianceEmpagliflozin | 12 | $6,644 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $37,384 | $111,984171 claims |
| Fresenius USA Marketing, Inc.Velphoro | $20 | $40,01214 claims |
| BayerKerendia | $26,968 | $29,21320 claims |
| Akebia Therapeutics IncAuryxia | $493 | $17,78217 claims |
| Boehringer IngelheimJardiance, Tradjenta | $88 | $12,06423 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,341 nephrology providers in California.
Other nephrology in Northridge
- Sohan DuaNorthridge$3.2M
- Ram PatakNorthridge$2M
- Dayan GandhiNorthridge$1M
- Anjay RastogiLos Angeles$6.3M
- Aamir JamalSan Dimas$5.5M
- Mohamed El-ShahawyLos Angeles$4.4M
- Kalpesh PatelCalabasas$3.6M
- Jehad HaggiagiMission Hills$3.6M
- Malvin YanSouth Gate$3.3M
- Richard LafayetteStanford$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.